For Immediate Release
For Further Information Contact:
Andrew Fisher at (301) 608-9292
Email: Afisher@unither.com

REMODULIN® REPORTED TO BE A SAFE AND EFFECTIVE TREATMENT FOR PULMONARY HYPERTENSION SECONDARY TO HIV INFECTION

Research Triangle Park, NC, May 13, 2003: United Therapeutics Corporation (NASDAQ: UTHR) today announced that the *SPANISH REVIEW OF CARDIOLOGY* reported the results of a one-year study in which United Therapeutics' lead product, Remodulin, demonstrated safety and efficacy for HIV-associated pulmonary arterial hypertension (2003; 56(4):421-25).

An estimated 1% of all persons with HIV manifest symptoms of pulmonary arterial hypertension. The recently published article, "Treatment of Pulmonary Hypertension Associated with HIV Infection with Treprostinil (Remodulin)", is the first such publication in a peer-reviewed journal to report success in treating HIV-associated pulmonary hypertension with a prostacyclin analog. The study was conducted at Madrid's Hospital Universitario 12 de Octubre. Remodulin, which received United States Food and Drug Administration approval on May 21, 2002 as a continuous subcutaneous infusion for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise, is approved to treat HIV-associated pulmonary arterial hypertension.

"We are very pleased to be able to confirm the benefits of Remodulin in additional types and sub-types of pulmonary arterial hypertension," said Martine Rothblatt, Ph.D., Chairman and CEO of United Therapeutics. "All too often patients are limited more by their pulmonary hypertension than by the condition that caused it. The hepatic safety and non-intravenous delivery features of Remodulin will hopefully enable many patients with pulmonary hypertension secondary to other conditions to receive treatment for this life-threatening disease."

Remodulin received Canadian Therapeutic Products Directorate approval on October 4, 2002 and approval from the Israeli Ministry of Health on October 31, 2002. United Therapeutics has submitted marketing applications for Remodulin in France, Switzerland and Australia, with additional European filings to follow approval in France. In clinical trials, the most common side effects reported with Remodulin therapy included infusion site pain (85%) and infusion site reaction (83%). Other adverse events included headache (27%), diarrhea (25%), nausea (22%), rash (14%), jaw pain (13%), vasodilatation (11%), dizziness (9%), edema (9%), pruritus (8%) and hypotension (4%). Remodulin should be used only by clinicians experienced in the diagnosis and treatment of pulmonary arterial hypertension.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.

* * *